Get started
Author

Maria Dam Ferdinez

ORCID: 0000-0002-3669-8872
Observed ORCID: 0000-0002-3669-8872
OpenAlex ID: A5042989254
VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
2022 · Julie A. Shields, Samuel R. Meier, et al. · Cancer Research · 63
PDF
Supplementary Figure S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Data from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al. · Cancer Research
Abstract 484: Hit finding and assay enablement for VRK1, a paralog synthetic lethal kinase target in VRK2-deficient cancers.
2026 · Katarzyna B. Handing, Kevin M. Cottrell, et al. · Cancer Research
Abstract 3090: VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cells
2026 · Kiera M. Vassallo, Kevin M. Cottrell, et al. · Cancer Research
Abstract 4252: Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers
2025 · Lauren Catherine M. Martires, Matthew Tonini, et al. · Cancer Research
Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
2023 · Julie A. Shields, Samuel R. Meier, et al.
Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
2023 · Julie A. Shields, Samuel R. Meier, et al.
Supplementary Figure from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
2023 · Julie A. Shields, Samuel R. Meier, et al.
PDF
Works count: 34
Citation count: 63
H-index: 1
I10-index: 1
Year
Topic
Type